Flindr

Flindr Therapeutics

This company develops small molecule inhibitors for the precision treatment of cancer patients with specific tumor and host factors.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.

KyDo

This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

CasInvent

This company develops selective casein kinase 1 inhibitors to treat resistant cancers, including leukaemias and solid tumours, for patients with limited treatment options.

MyCural Therapeutics

This company develops small molecule drugs targeting the MYC oncoprotein to treat patients with aggressive, high-risk cancers.